. Bartolome-r and M. D. Celli,

M. D. Marc-decramer and . D. Ph,

J. A. Wedzicha, M. D. , and F. R. ,

K. C. Wilson, M. D. Agustí, M. D. Gerard-j.-criner, M. D. William-macnee, M. D. et al., Group leaders: ALVAR

M. D. Antonio-anzueto,

D. H. Au, M. D. , and M. S. ,

P. J. Barnes, D. M. , D. Sc, F. R. Pierre-regis, M. D. Burgel et al.,

P. M. Calverley, M. B. Ch, D. Sc, and M. Casanova,

E. M. Clini, M. D. Christopher-b, M. D. Cooper, . Harvey-o, and P. D. Coxson,

D. J. Dusser and M. D. ,

L. M. Fabbri, M. D. Fahy, R. N. , M. N. , C. N. Gary-t et al.,

B. M. Andrew-fisher, . Sci, and . D. Ph,

M. J. Fletcher, R. N. , and M. S. ,

M. D. Maurice-hayot, . D. Ph, . John-r, M. D. Hurst, . Paul-w et al.,

D. M. Mannino, M. D. Fernando, M. D. Martinez, M. S. Marc-miravitlles, M. D. et al., Pfizer ($1-4,999), and Vifor Pharma ($1-4,999); all corporate support was paid to her institution. K.C.W. owned investment accounts held with State Street Bank that were independently managed by Moody Lynn and Co. and may have included healthcare-related holdings. G.J.C. received research support involving payments to his institution from Forest, Author Disclosures: B.R.C. was a consultant to AstraZeneca, vol.999, issue.5, pp.0-249

, Boehringer Ingelheim ($1-4,999), Celerion ($1-4,999, 999). W.M. received research support from GlaxoSmithKline and Pfizer, and was on advisory committees of Almirall, vol.999, pp.0-24

, AstraZeneca

. Novartis, Novartis ($5,000-24,999), and Sunovion Pharmaceuticals ($1-4,999); he also served on advisory committees and as a speaker for Abbott ($1-4,999, Johnson & Johnson ($1-4,999), MedImmune ($1-4,999), Merck ($1-4,999), Novartis ($1-4,999), Nycomed ($1-4,999), Pearl ($5,000-24,999), Pulmatrix ($1-4,999), Regeneron ($5,000-24,999), and Takeda, vol.100, pp.0-49

, Boehringer Ingelheim (amount not noted), and a consultant to Takeda (amount not noted); he was a speaker for Boehringer Ingelheim, M.C. was on advisory committees for AstraZeneca, vol.5, pp.0-24

B. , Boehringer Ingelheim, Novartis, and Pearl; he was a speaker for Boehringer Ingelheim, Forest, and GlaxoSmithKline (amounts not noted), G.T.F. received research support from AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, and Pearl, and was on advisory committees of AstraZeneca, CSL Behring, vol.25, pp.1-5

P. W. , 999) and was a consultant and speaker for GlaxoSmithKline ($25,000-49,999); he was on an advisory committee and a speaker for Almirall, vol.100, pp.0-24

D. A. , did contracted research for AstraZeneca, Novartis, and Takeda, and was a consultant and speaker for Boehringer Ingelheim (amounts not noted); he was on an advisory committee and a speaker for GlaxoSmithKline ($5,000-24,999); he was a speaker for Novartis and Nycomed (amounts not noted, GlaxoSmithKline, Novartis, and Sunovion and received royalties from MAPI Research Institute and Taylor & Francis (amounts not noted). F.M. received research support from Boehringer Ingelheim, vol.100, pp.0-24

F. J. , Centocor (no payments), Cory Path ($1-4,999), Forest ($25, Merion ($1-4,999), Nycomed/Takeda ($5,000-24,999), and Sudler and Hennessey ($1-4,999); he was on advisory committees of AstraZeneca ($1-4,999), Boehringer Ingelheim, vol.999, pp.0-24

, Novartis ($5,000-24,999), and Takeda ($5,000-24,999). A.P. received research support from AstraZeneca, he received royalties from Informa ($1-4,999). M.M. was on advisory committees and a speaker for Almirall ($1-4,999), AstraZeneca ($1-4,999, vol.999, pp.0-24

K. F. Astrazeneca, B. Ingelheim, . Chiesi, ;. Glaxosmithkline, M. Sharp-&-dohme et al., ), a consultant and speaker for Nycomed ($1-4,999), and on advisory committees and a speaker for AstraZeneca ($5,000-24,999), Novartis ($25,000-99,999), Pfizer ($5,000-24,999), Pearl ($5, vol.999, pp.0-24

R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya et al., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study, Lancet, vol.380, pp.2095-2128, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00827612

A. M. Miniño, J. Xu, and K. D. Kochanek, Deaths: preliminary data for, Natl Vital Stat Rep, vol.59, pp.1-52, 2008.

J. L. López-campos, M. Ruiz-ramos, and J. B. Soriano, Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis, Lancet Respir Med, vol.2, pp.54-62, 2014.

C. J. Murray and A. D. Lopez, Measuring the global burden of disease, N Engl J Med, vol.369, pp.448-457, 2013.

M. J. Thun, B. D. Carter, D. Feskanich, N. D. Freedman, R. Prentice et al., 50-year trends in smoking-related mortality in the United States, N Engl J Med, vol.368, pp.351-364, 2013.

A. J. Guarascio, S. M. Ray, C. K. Finch, and T. H. Self, The clinical and economic burden of chronic obstructive pulmonary disease in the USA, Clinicoecon Outcomes Res, vol.5, pp.235-245, 2013.

B. R. Celli, W. Macnee, A. Agusti, A. Anzueto, B. Berg et al., ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper, Eur Respir J, vol.23, pp.932-946, 2004.

J. Vestbo, S. S. Hurd, A. G. Agustí, P. W. Jones, C. Vogelmeier et al., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med, vol.187, pp.347-365, 2013.

J. O'reilly, M. M. Jones, J. Parnham, K. Lovibond, and R. M. , Guideline Development Group. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance, BMJ, vol.340, p.3134, 2010.

B. L. Rostron, C. M. Chang, and T. F. Pechacek, Estimation of cigarette smokingattributable morbidity in the United States, JAMA Intern Med, vol.174, pp.1922-1928, 2014.

K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke et al., Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, Lancet, vol.380, pp.37-43, 2012.

P. Jones, M. Miravitlles, T. Van-der-molen, and K. Kulich, Beyond FEV? in COPD: a review of patient-reported outcomes and their measurement, Int J Chron Obstruct Pulmon Dis, vol.7, pp.697-709, 2012.

N. Roche, J. Gaillat, M. Garre, J. P. Meunier, N. Lemaire et al., Acute respiratory illness as a trigger for detecting chronic bronchitis in adults at risk of COPD: a primary care survey, Prim Care Respir J, vol.19, pp.371-377, 2010.

C. G. Cote, C. Casanova, J. M. Marín, M. V. Lopez, V. Pinto-plata et al., Validation and comparison of reference equations for the 6-min walk distance test, Eur Respir J, vol.31, pp.571-578, 2008.

T. Oga, K. Nishimura, M. Tsukino, S. Sato, and T. Hajiro, Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status, Am J Respir Crit Care Med, vol.167, pp.544-549, 2003.

H. O. Coxson and S. Lam, Quantitative assessment of the airway wall using computed tomography and optical coherence tomography, Proc Am Thorac Soc, vol.6, pp.439-443, 2009.

S. J. Copley, A. U. Wells, N. L. Müller, M. B. Rubens, N. P. Hollings et al., Thin-section CT in obstructive pulmonary disease: discriminatory value, Radiology, vol.223, pp.812-819, 2002.

H. O. Coxson, J. Mayo, S. Lam, G. Santyr, G. Parraga et al., New and current clinical imaging techniques to study chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.180, pp.588-597, 2009.

R. G. Barr, E. A. Berkowitz, F. Bigazzi, F. Bode, J. Bon et al., COPDGene CT Workshop Group. A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation, COPD, vol.9, pp.151-159, 2012.

C. J. Galbán, M. K. Han, J. L. Boes, K. A. Chughtai, C. R. Meyer et al., Computed tomographybased biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression, Nat Med, vol.18, pp.1711-1715, 2012.

A. Christe, J. Charimo-torrente, K. Roychoudhury, P. Vock, and J. E. Roos, Accuracy of low-dose computed tomography (CT) for detecting and characterizing the most common CT-patterns of pulmonary disease, Eur J Radiol, vol.82, pp.142-150, 2013.

P. J. Castaldi, S. Estépar, R. Mendoza, C. S. Hersh, C. P. Laird et al., Distinct quantitative computed tomography emphysema patterns are associated with physiology and function in smokers, Am J Respir Crit Care Med, vol.188, pp.1083-1090, 2013.

H. O. Coxson, J. Leipsic, G. Parraga, and D. D. Sin, Using pulmonary imaging to move COPD beyond FEV1, Am J Respir Crit Care Med, vol.190, pp.135-144, 2014.

J. P. De-torres, J. M. Marín, C. Casanova, C. Cote, S. Carrizo et al., Lung cancer in patients with chronic obstructive pulmonary disease-incidence and predicting factors, Am J Respir Crit Care Med, vol.184, pp.913-919, 2011.

J. A. Hardie, A. S. Buist, W. M. Vollmer, I. Ellingsen, P. S. Bakke et al., Risk of over-diagnosis of COPD in asymptomatic elderly neversmokers, Eur Respir J, vol.20, pp.1117-1122, 2002.

I. Cerveri, A. G. Corsico, S. Accordini, R. Niniano, E. Ansaldo et al., Underestimation of airflow obstruction among young adults using FEV1/FVC ,70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes, Thorax, vol.63, pp.1040-1045, 2008.

S. P. Bhatt, J. C. Sieren, M. T. Dransfield, G. R. Washko, J. D. Newell et al., COPDGene Investigators. Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction, Thorax, vol.69, pp.409-414, 2014.

A. C. Carlsson, P. Wändell, U. Ösby, R. Zarrinkoub, B. Wettermark et al., High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden -a challenge for public health, BMC Public Health, vol.13, pp.670-678, 2013.

P. O. Bridevaux, M. W. Gerbase, N. M. Probst-hensch, C. Schindler, J. M. Gaspoz et al., Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD, Thorax, vol.63, pp.768-774, 2008.

U. S. , Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, vol.148, pp.529-534, 2008.

M. Ferrer, J. Alonso, J. Morera, R. M. Marrades, A. Khalaf et al., The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Chronic obstructive pulmonary disease stage and health-related quality of life, Ann Intern Med, vol.127, pp.1072-1079, 1997.

M. Friedman, C. W. Serby, S. S. Menjoge, J. D. Wilson, D. E. Hilleman et al., Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD, Chest, vol.115, pp.635-641, 1999.

P. S. Burge, P. M. Calverley, P. W. Jones, S. Spencer, J. A. Anderson et al., Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial, BMJ, vol.320, pp.1297-1303, 2000.

N. A. Dewan, S. Rafique, B. Kanwar, H. Satpathy, K. Ryschon et al., Acute exacerbation of COPD: factors associated with poor treatment outcome, Chest, vol.117, pp.662-671, 2000.

N. R. Anthonisen, E. C. Wright, and J. E. Hodgkin, Prognosis in chronic obstructive pulmonary disease, Am Rev Respir Dis, vol.133, pp.14-20, 1986.

B. R. Celli, R. J. Halbert, S. Isonaka, and B. Schau, Population impact of different definitions of airway obstruction, Eur Respir J, vol.22, pp.268-273, 2003.

M. B. Parshall, R. M. Schwartzstein, L. Adams, R. B. Banzett, H. L. Manning et al., statement: update on the mechanisms, assessment, and management of dyspnea, Am J Respir Crit Care Med, vol.185, pp.435-452, 2012.

A. M. Schols, J. Slangen, L. Volovics, and E. F. Wouters, Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.157, pp.1791-1797, 1998.

C. Landbo, E. Prescott, P. Lange, J. Vestbo, and T. P. Almdal, Prognostic value of nutritional status in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.160, pp.1856-1861, 1999.

D. A. Mahler, J. Ward, L. A. Waterman, C. Mccusker, R. Zuwallack et al., Patient-reported dyspnea in COPD reliability and association with stage of disease, Chest, vol.136, pp.1473-1479, 2009.

K. Nishimura, T. Izumi, M. Tsukino, and T. Oga, Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD, Chest, vol.121, pp.1434-1440, 2002.

J. Garcia-aymerich, P. Lange, M. Benet, P. Schnohr, and J. M. Antó, Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study, Thorax, vol.61, pp.772-778, 2006.

B. R. Celli, C. G. Cote, J. M. Marin, C. Casanova, M. Montes-de-oca et al., The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med, vol.350, pp.1005-1012, 2004.

C. G. Cote, V. M. Pinto-plata, J. M. Marin, H. Nekach, L. J. Dordelly et al., The modified BODE index: validation with mortality in COPD, Eur Respir J, vol.32, pp.1269-1274, 2008.

J. J. Soler-cataluña, M. A. Martínez-garcía, L. S. Sánchez, M. P. Tordera, and P. R. Sánchez, Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients, Respir Med, vol.103, pp.692-699, 2009.

J. M. Marin, I. Alfageme, P. Almagro, C. Casanova, C. Esteban et al., Multicomponent indices to predict survival in COPD: the COCOMICS study, Eur Respir J, vol.42, pp.323-332, 2013.

B. R. Celli, N. Locantore, J. Yates, R. Tal-singer, B. E. Miller et al., Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease, ECLIPSE Investigators, vol.185, pp.1065-1072, 2012.

M. A. Puhan, J. Garcia-aymerich, M. Frey, G. Ter-riet, J. M. Antó et al., Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index, Lancet, vol.374, pp.704-711, 2009.

R. C. Jones, G. C. Donaldson, N. H. Chavannes, K. Kida, M. Dickson-spillmann et al., Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index, Am J Respir Crit Care Med, vol.180, pp.1189-1195, 2009.

P. Almagro, J. B. Soriano, F. J. Cabrera, R. Boixeda, M. B. Alonso-ortiz et al., Working Group on COPD, Spanish Society of Internal Medicine. Short-and mediumterm prognosis in patients hospitalized for COPD exacerbation: the CODEX index, Chest, vol.145, pp.972-980, 2014.

P. Lange, J. L. Marott, J. Vestbo, K. R. Olsen, T. S. Ingebrigtsen et al., Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population, Am J Respir Crit Care Med, vol.186, pp.975-981, 2012.

J. B. Soriano, I. Alfageme, P. Almagro, C. Casanova, C. Esteban et al., Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification, Chest, vol.143, pp.694-702, 2013.

A. Johannessen, R. M. Nilsen, M. Storebø, A. Gulsvik, T. Eagan et al., Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization, Am J Respir Crit Care Med, vol.188, pp.51-59, 2013.

M. Divo, C. Cote, J. P. De-torres, C. Casanova, J. M. Marin et al., BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.186, pp.155-161, 2012.

A. Agustí, J. A. Barberà, E. Wouters, V. I. Peinado, and P. K. Jeffery, Lungs, bone marrow, and adipose tissue. A network approach to the pathobiology of chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.188, pp.1396-1406, 2013.

G. C. Donaldson, T. Seemungal, A. Bhowmik, and J. A. Wedzicha, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease, Thorax, vol.57, pp.847-852, 2002.

J. Vestbo, L. D. Edwards, P. D. Scanlon, J. C. Yates, A. Agusti et al., Changes in forced expiratory volume in 1 second over time in COPD, ECLIPSE Investigators, vol.365, pp.1184-1192, 2011.

A. Agusti, P. M. Calverley, B. Celli, H. O. Coxson, L. D. Edwards et al., Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort, Respir Res, vol.11, pp.122-136, 2010.

N. Freimer and C. Sabatti, The human phenome project, Nat Genet, vol.34, pp.15-21, 2003.

M. K. Han, A. Agusti, P. M. Calverley, B. R. Celli, G. Criner et al., Chronic obstructive pulmonary disease phenotypes: the future of COPD, Am J Respir Crit Care Med, vol.182, pp.598-604, 2010.

J. M. Drazen and L. M. Fabbri, Ageing and multimorbidity, Eur Respir J, vol.44, p.557, 2014.

R. Faner, T. Cruz, A. López-giraldo, and A. Agustí, Network medicine, multimorbidity and the lung in the elderly, Eur Respir J, vol.44, pp.775-788, 2014.

M. J. Divo, C. H. Martinez, and D. M. Mannino, Ageing and the epidemiology of multimorbidity, Eur Respir J, vol.44, pp.1055-1068, 2014.

A. R. Patel, G. C. Donaldson, A. J. Mackay, J. A. Wedzicha, and J. R. Hurst, The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD, Chest, vol.141, pp.851-857, 2012.

D. M. Mannino, D. Thorn, A. Swensen, and F. Holguin, Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD, Eur Respir J, vol.32, pp.962-969, 2008.

D. O. Wilson, J. K. Leader, C. R. Fuhrman, J. J. Reilly, F. C. Sciurba et al., Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the Pittsburgh lung screening study, J Thorac Oncol, vol.6, pp.1200-1205, 2011.

P. M. Calverley, J. A. Anderson, B. Celli, G. T. Ferguson, C. Jenkins et al., Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease, N Engl J Med, vol.356, pp.775-789, 2007.

L. E. Vanfleteren, M. A. Spruit, M. Groenen, S. Gaffron, V. P. Van-empel et al., Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.187, pp.728-735, 2013.

M. Roca, A. Verduri, L. Corbetta, E. Clini, L. M. Fabbri et al., Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease, Eur J Clin Invest, vol.43, pp.510-521, 2013.

G. C. Donaldson, J. R. Hurst, C. J. Smith, R. B. Hubbard, and J. A. Wedzicha, Increased risk of myocardial infarction and stroke following exacerbation of COPD, Chest, vol.137, pp.1091-1097, 2010.

R. P. Bowler, V. Kim, R. E. Williams, A. Santorico, S. A. Make et al., COPDGene Investigators. Prediction of acute respiratory disease in current and former smokers with and without COPD, Chest, vol.146, pp.941-950, 2014.

W. C. Tan, J. Bourbeau, P. Hernandez, K. R. Chapman, R. Cowie et al., CanCOLD Collaborative Research Group. Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study, Thorax, vol.69, pp.709-717, 2014.

J. M. Marin, J. B. Soriano, S. J. Carrizo, A. Boldova, and B. R. Celli, Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome, Am J Respir Crit Care Med, vol.182, pp.325-331, 2010.

J. E. Repine and A. Bast, Lankhorst I; Oxidative Stress Study Group. Oxidative stress in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.156, pp.341-357, 1997.

E. G. Tzortzaki and N. M. Siafakas, A hypothesis for the initiation of COPD, Eur Respir J, vol.34, pp.310-315, 2009.

S. Sethi and T. F. Murphy, Infection in the pathogenesis and course of chronic obstructive pulmonary disease, N Engl J Med, vol.359, pp.2355-2365, 2008.

A. A. Pragman, H. B. Kim, C. S. Reilly, C. Wendt, and R. E. Isaacson, The lung microbiome in moderate and severe chronic obstructive pulmonary disease, PLoS ONE, vol.7, p.47305, 2012.

M. G. Cosio, M. Saetta, and A. Agusti, Immunologic aspects of chronic obstructive pulmonary disease, N Engl J Med, vol.360, pp.2445-2454, 2009.

I. K. Demedts, T. Demoor, K. R. Bracke, G. F. Joos, and G. G. Brusselle, Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema, Respir Res, vol.7, p.53, 2006.

R. Faner, M. Rojas, W. Macnee, and A. Agustí, Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, vol.186, pp.306-313, 2012.

Q. Yang, M. J. Underwood, M. K. Hsin, X. C. Liu, and G. W. He, Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development, Curr Drug Metab, vol.9, pp.661-667, 2008.

A. Rab, S. M. Rowe, S. V. Raju, Z. Bebok, S. Matalon et al., Cigarette smoke and CFTR: implications in the pathogenesis of COPD, Am J Physiol Lung Cell Mol Physiol, vol.305, pp.530-541, 2013.

M. Saetta, D. Stefano, A. Turato, G. Facchini, F. M. Corbino et al., CD81 T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.157, pp.822-826, 1998.

S. I. Rennard, Inflammation and repair processes in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.160, pp.12-16, 1999.

V. I. Peinado, J. A. Barberá, P. Abate, J. Ramírez, J. Roca et al., Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.159, pp.1605-1611, 1999.

R. Rodriguez-roisin and W. Macnee, Pathophysiology of chronic obstructive pulmonary disease, Eur Respir Mon, vol.3, pp.107-126, 1998.

T. C. O'shaughnessy, T. W. Ansari, N. C. Barnes, and P. K. Jeffery, Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD81 T lymphocytes with FEV1, Am J Respir Crit Care Med, vol.155, pp.852-857, 1997.

K. Matsuba, J. L. Wright, B. R. Wiggs, P. D. Pare, and J. C. Hogg, The changes in airways structure associated with reduced forced expiratory volume in one second, Eur Respir J, vol.2, pp.834-839, 1989.

D. E. O'donnell, S. M. Revill, and K. A. Webb, Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.164, pp.770-777, 2001.

P. Jha and R. Peto, Global effects of smoking, of quitting, and of taxing tobacco, N Engl J Med, vol.370, pp.60-68, 2014.

N. R. Anthonisen, J. E. Connett, and R. P. Murray, Smoking and lung function of Lung Health Study participants after 11 years, Am J Respir Crit Care Med, vol.166, pp.675-679, 2002.

G. Parkes, T. Greenhalgh, M. Griffin, and R. Dent, Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial, BMJ, vol.336, pp.598-600, 2008.

M. Bednarek, D. Gorecka, J. Wielgomas, M. Czajkowska-malinowska, J. Regula et al., Smokers with airway obstruction are more likely to quit smoking, Thorax, vol.61, pp.869-873, 2006.

G. Stratelis, S. Mölstad, P. Jakobsson, and O. Zetterström, The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD, Scand J Prim Health Care, vol.24, pp.133-139, 2006.

D. Kotz, G. Wesseling, M. Huibers, and O. Van-schayck, Efficacy of confronting smokers with airflow limitation for smoking cessation, Eur Respir J, vol.33, pp.754-762, 2009.

C. A. Jiménez-ruiz, F. Masa, M. Miravitlles, R. Gabriel, J. L. Viejo et al., Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD, Chest, vol.119, pp.1365-1370, 2001.

D. Tashkin, R. Kanner, W. Bailey, S. Buist, P. Anderson et al., Smoking cessation in patients with chronic obstructive pulmonary disease: a doubleblind, placebo-controlled, randomised trial, Lancet, vol.357, pp.1571-1575, 2001.

D. P. Tashkin, S. Rennard, J. T. Hays, W. Ma, D. Lawrence et al., Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial, Chest, vol.139, pp.591-599, 2011.

P. Tønnesen, K. Mikkelsen, and L. Bremann, Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support, Chest, vol.130, pp.334-342, 2006.

E. J. Wagena, R. M. Van-der-meer, R. J. Ostelo, J. E. Jacobs, and C. P. Van-schayck, The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review, Respir Med, vol.98, pp.805-815, 2004.

I. Wilson, Depression in the patient with COPD, Int J Chron Obstruct Pulmon Dis, vol.1, pp.61-64, 2006.

N. A. Rigotti, A. L. Pipe, N. L. Benowitz, C. Arteaga, D. Garza et al., Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial, Circulation, vol.121, pp.221-229, 2010.

B. M. Kuehn, Updated US smoking cessation guideline advises counseling, combining therapies, JAMA, vol.299, p.2736, 2008.

S. D. Shah, L. A. Wilken, S. R. Winkler, and S. Lin, Systematic review and meta-analysis of combination therapy for smoking cessation, J Am Pharm Assoc, vol.48, pp.659-665, 2003.

M. B. Steinberg, S. Greenhaus, A. C. Schmelzer, M. T. Bover, J. Foulds et al., Triple-combination pharmacotherapy for medically ill smokers: a randomized trial, Ann Intern Med, vol.150, pp.447-454, 2009.

M. E. Piper, S. S. Smith, T. R. Schlam, M. C. Fiore, D. E. Jorenby et al., A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies, Arch Gen Psychiatry, vol.66, pp.1253-1262, 2009.

E. F. Ellerbeck, J. D. Mahnken, A. P. Cupertino, L. S. Cox, K. A. Greiner et al., Effect of varying levels of disease management on smoking cessation: a randomized trial, Ann Intern Med, vol.150, pp.437-446, 2009.

M. C. Fiore, C. R. Jaen, T. B. Baker, W. C. Bailey, N. L. Benowitz et al., Treating tobacco use and dependence: 2008 update. Clinical practice guidelines, 2008.

T. J. Crowley, M. J. Macdonald, and M. I. Walter, Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients, Psychopharmacology (Berl), vol.119, pp.193-204, 1995.

J. Etter, C. Bullen, A. D. Flouris, M. Laugesen, and T. Eissenberg, Electronic nicotine delivery systems: a research agenda, Tob Control, vol.20, pp.243-248, 2011.

J. Etter and C. Bullen, Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy, Addiction, vol.106, pp.2017-2028, 2011.

M. L. Goniewicz, E. O. Lingas, and P. Hajek, Patterns of electronic cigarette use and user beliefs about their safety and benefits: an internet survey, Drug Alcohol Rev, vol.32, pp.133-140, 2013.

J. F. Bertholon, M. H. Becquemin, I. Annesi-maesano, and B. Dautzenberg, Electronic cigarettes: a short review, Respiration, vol.86, pp.433-438, 2013.

D. E. Schraufnagel, F. Blasi, M. B. Drummond, D. Lam, E. Latif et al., Forum of International Respiratory Societies. Electronic cigarettes: a position statement of the forum of international respiratory societies, Am J Respir Crit Care Med, vol.190, pp.611-618, 2014.

A. S. Buist, G. J. Sexton, J. M. Nagy, and B. B. Ross, The effect of smoking cessation and modification on lung function, Am Rev Respir Dis, vol.114, pp.115-122, 1976.

C. Jiménez-ruiz, S. Solano, S. A. Viteri, M. B. Ferrero, M. Torrecilla et al., Harm reduction-a treatment approach for resistant smokers with tobacco-related symptoms, Respiration, vol.69, pp.452-455, 2002.

S. I. Rennard, D. Daughton, J. Fujita, M. B. Oehlerking, J. R. Dobson et al., Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers, Eur Respir J, vol.3, pp.752-759, 1990.

M. S. Simmons, J. E. Connett, M. A. Nides, P. G. Lindgren, E. C. Kleerup et al., Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study, Eur Respir J, vol.25, pp.1011-1017, 2005.

J. R. Hughes and M. J. Carpenter, Does smoking reduction increase future cessation and decrease disease risk? A qualitative review, Nicotine Tob Res, vol.8, pp.739-749, 2006.

R. Boyle, L. Solberg, and M. Fiore, Use of electronic health records to support smoking cessation, Cochrane Database Syst Rev, vol.12, p.8743, 2011.

J. M. Tetrault, K. Crothers, B. A. Moore, R. Mehra, J. Concato et al., Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review, Arch Intern Med, vol.167, pp.221-228, 2007.

D. P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten et al., UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease, N Engl J Med, vol.359, pp.1543-1554, 2008.

C. R. Jenkins, P. W. Jones, P. M. Calverley, B. Celli, J. A. Anderson et al., Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study, Respir Res, vol.10, p.59, 2009.

P. R. Burgel, J. L. Paillasseur, D. Dusser, N. Roche, D. Liu et al., Decramer M; UPLIFT® Study Investigators. Tiotropium might improve survival in subjects with COPD at high risk of mortality, Respir Res, vol.15, p.64, 2014.

B. R. Celli, N. E. Thomas, J. A. Anderson, G. T. Ferguson, C. R. Jenkins et al., Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study, Am J Respir Crit Care Med, vol.178, pp.332-338, 2008.

M. Decramer, B. Celli, S. Kesten, T. Lystig, S. Mehra et al., UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial, Lancet, vol.374, pp.1171-1178, 2009.

P. R. Burgel, J. L. Paillasseur, B. Peene, D. Dusser, N. Roche et al., Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality, PLoS ONE, vol.7, p.51048, 2012.

E. D. Bateman, C. Feldman, J. O'brien, M. Plit, and J. R. Joubert, Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision, S Afr Med J, vol.94, pp.559-575, 2004.

J. A. Wedzicha, M. Decramer, and T. A. Seemungal, The role of bronchodilator treatment in the prevention of exacerbations of COPD, Eur Respir J, vol.40, pp.1545-1554, 2012.

M. K. Han, N. Tayob, S. Murray, M. T. Dransfield, G. Washko et al., Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy, Am J Respir Crit Care Med, vol.189, pp.1503-1508, 2014.

J. Chong, C. Karner, and P. Poole, Tiotropium versus long-acting betaagonists for stable chronic obstructive pulmonary disease, Cochrane Database Syst Rev, vol.9, p.9157, 2012.

K. F. Rabe, L. M. Fabbri, E. Israel, H. Kogler, K. Riemann et al., Effect of ADRB2 polymorphism on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial, Lancet Respir Med, vol.2, pp.44-53, 2014.

M. L. Decramer, K. R. Chapman, R. Dahl, P. Frith, G. Devouassoux et al., Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study, Lancet Respir Med, vol.1, pp.524-533, 2013.

P. M. Calverley, R. A. Stockley, T. A. Seemungal, G. Hagan, L. R. Willits et al., Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study, Chest, vol.139, pp.505-512, 2011.

C. Crim, P. M. Calverley, J. A. Anderson, B. Celli, G. T. Ferguson et al., Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results, Eur Respir J, vol.34, pp.641-647, 2009.

J. A. Wedzicha, P. M. Calverley, T. A. Seemungal, G. Hagan, Z. Ansari et al., The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide, Am J Respir Crit Care Med, vol.177, pp.19-26, 2008.

S. D. Aaron, K. L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau et al., Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial, Ann Intern Med, vol.146, pp.545-555, 2007.

J. A. Wedzicha, M. Decramer, J. H. Ficker, D. E. Niewoehner, T. Sandström et al., Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study, Lancet Respir Med, vol.1, pp.199-209, 2013.

P. M. Short, P. A. Williamson, D. H. Elder, S. I. Lipworth, S. Schembri et al., The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and longacting b-agonist therapy in COPD, Chest, vol.141, pp.81-86, 2012.

K. S. Jung, H. Y. Park, S. Y. Park, S. K. Kim, Y. K. Kim et al., Korean Academy of Tuberculosis and Respiratory Diseases study group; Korea Chronic Obstructive Pulmonary Disease study group. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study, Respir Med, vol.106, pp.382-389, 2012.

H. Magnussen, B. Disse, R. Rodriguez-roisin, K. A. Watz, H. Tetzlaff et al., WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD, N Engl J Med, vol.371, pp.1285-1294, 2014.

J. W. Dodd, L. Hogg, J. Nolan, H. Jefford, A. Grant et al., The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study, Thorax, vol.66, pp.425-429, 2011.

P. W. Jones, G. Harding, P. Berry, I. Wiklund, W. H. Chen et al., Development and first validation of the COPD Assessment Test, Eur Respir J, vol.34, pp.648-654, 2009.

P. W. Jones, G. Harding, I. Wiklund, P. Berry, M. Tabberer et al., Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation, Chest, vol.142, pp.134-140, 2012.

J. Vestbo, J. A. Anderson, P. M. Calverley, B. Celli, G. T. Ferguson et al., Adherence to inhaled therapy, mortality and hospital admission in COPD, Thorax, vol.64, pp.939-943, 2009.

E. L. Toy, N. U. Beaulieu, J. M. Mchale, T. R. Welland, C. A. Plauschinat et al., Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs, Respir Med, vol.105, pp.435-441, 2011.

P. Barnestein-fonseca, J. Leiva-fernández, F. Vidal-españa, A. García-ruiz, D. Prados-torres et al., Efficacy and safety of a multifactor intervention to improve therapeutic adherence in patients with chronic obstructive pulmonary disease (COPD): protocol for the ICEPOC study, Trials, vol.12, p.40, 2011.

A. S. Melani, M. Bonavia, V. Cilenti, C. Cinti, M. Lodi et al., Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri. Inhaler mishandling remains common in real life and is associated with reduced disease control, Respir Med, vol.105, pp.930-938, 2011.

W. Vincken, P. R. Dekhuijzen, P. Barnes, and . Group, The ADMIT series -Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD, Prim Care Respir J, vol.19, pp.10-20, 2010.

B. L. Laube, H. M. Janssens, F. De-jongh, S. G. Devadason, R. Dhand et al., What the pulmonary specialist should know about the new inhalation therapies, International Society for Aerosols in Medicine, vol.37, pp.1308-1331, 2011.

M. J. Sevenoaks and R. A. Stockley, Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity-a common inflammatory phenotype?, Respir Res, vol.7, p.70, 2006.

P. J. Barnes, New anti-inflammatory targets for chronic obstructive pulmonary disease, Nat Rev Drug Discov, vol.12, pp.543-559, 2013.

G. G. Brusselle, G. F. Joos, and K. R. Bracke, New insights into the immunology of chronic obstructive pulmonary disease, Lancet, vol.378, pp.1015-1026, 2011.

S. I. Rennard, C. Fogarty, S. Kelsen, W. Long, J. Ramsdell et al., COPD Investigators. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.175, pp.926-934, 2007.

C. E. Brightling, E. R. Bleecker, R. A. Panettieri, M. Bafadhel, D. She et al., Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomized, double-blind, placebo-controlled, phase 2a study, Lancet Respir Med, vol.2, pp.891-901, 2014.

J. Chong, P. Poole, B. Leung, and P. N. Black, Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease, Cochrane Database Syst Rev, vol.5, p.2309, 2011.

D. J. Powrie, T. M. Wilkinson, G. C. Donaldson, P. Jones, K. Scrine et al., Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD, Eur Respir J, vol.30, pp.472-478, 2007.

D. A. Lomas, D. A. Lipson, B. E. Miller, L. Willits, O. Keene et al., Tal-Singer R; Losmapimod Study Investigators. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease, J Clin Pharmacol, vol.52, pp.416-424, 2012.

H. Watz, H. Barnacle, B. F. Hartley, and R. Chan, Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial, Lancet Respir Med, vol.2, pp.63-72, 2014.

P. J. Barnes and I. M. Adcock, Glucocorticoid resistance in inflammatory diseases, Lancet, vol.373, pp.1905-1917, 2009.

M. Bafadhel, L. Davies, P. M. Calverley, S. D. Aaron, C. E. Brightling et al., Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis, Eur Respir J, vol.44, pp.789-791, 2014.

M. Bafadhel, S. Mckenna, S. Terry, V. Mistry, M. Pancholi et al., Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebocontrolled trial, Am J Respir Crit Care Med, vol.186, pp.48-55, 2012.

H. Ortega, H. Li, R. Suruki, F. Albers, D. Gordon et al., Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma, Ann Am Thorac Soc, vol.11, pp.1011-1017, 2014.

I. D. Pavord, S. Korn, P. Howarth, E. R. Bleecker, R. Buhl et al., Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, Lancet, vol.380, pp.651-659, 2012.

S. Hodge, G. Hodge, H. Jersmann, G. Matthews, J. Ahern et al., Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.178, pp.139-148, 2008.

M. Yamaya, A. Azuma, H. Takizawa, J. Kadota, J. Tamaoki et al., Macrolide effects on the prevention of COPD exacerbations, Eur Respir J, vol.40, pp.485-494, 2012.

R. K. Albert, J. Connett, W. C. Bailey, R. Casaburi, J. A. Cooper et al., Azithromycin for prevention of exacerbations of COPD, COPD Clinical Research Network, vol.365, pp.689-698, 2011.

T. A. Seemungal, T. M. Wilkinson, J. R. Hurst, W. R. Perera, R. J. Sapsford et al., Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations, Am J Respir Crit Care Med, vol.178, pp.1139-1147, 2008.

W. A. Ray, K. T. Murray, K. Hall, P. G. Arbogast, and C. M. Stein, Azithromycin and the risk of cardiovascular death, N Engl J Med, vol.366, pp.1881-1890, 2012.

W. A. Ray, K. T. Murray, S. Meredith, S. S. Narasimhulu, K. Hall et al., Oral erythromycin and the risk of sudden death from cardiac causes, N Engl J Med, vol.351, pp.1089-1096, 2004.

H. Svanström, B. Pasternak, and A. Hviid, Use of azithromycin and death from cardiovascular causes, N Engl J Med, vol.368, pp.1704-1712, 2013.

S. Sethi, P. W. Jones, M. S. Theron, M. Miravitlles, E. Rubinstein et al., PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial, Respir Res, vol.11, p.10, 2010.

L. Marin, P. Colombo, M. Bebawy, P. M. Young, and D. Traini, Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management, Expert Opin Drug Deliv, vol.8, pp.1205-1220, 2011.

R. P. Young, R. Hopkins, and T. E. Eaton, Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence, Postgrad Med J, vol.85, pp.414-421, 2009.

M. Bando, T. Miyazawa, H. Shinohara, T. Owada, M. Terakado et al., An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease, Respirology, vol.17, pp.493-498, 2012.

K. Bartziokas, A. I. Papaioannou, M. Minas, K. Kostikas, W. Banya et al., Statins and outcome after hospitalization for COPD exacerbation: a prospective study, Pulm Pharmacol Ther, vol.24, pp.625-631, 2011.

S. Janda, K. Park, J. M. Fitzgerald, M. Etminan, and J. Swiston, Statins in COPD: a systematic review, Chest, vol.136, pp.734-743, 2009.

C. C. Dobler, K. K. Wong, and G. B. Marks, Associations between statins and COPD: a systematic review, BMC Pulm Med, vol.9, p.32, 2009.

T. M. Lee, C. C. Chen, H. N. Shen, and N. C. Chang, Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension, Clin Sci, vol.116, pp.497-505, 2009.

G. J. Criner, J. E. Connett, S. D. Aaron, R. K. Albert, W. C. Bailey et al., Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-tosevere COPD, COPD Clinical Research, vol.370, pp.2201-2210, 2014.

L. C. Price, D. Lowe, H. S. Hosker, K. Anstey, M. G. Pearson et al.,

, UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation, Thorax, vol.61, pp.837-842, 2006.

F. H. Rutten, N. P. Zuithoff, E. Hak, D. E. Grobbee, and A. W. Hoes, Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease, Arch Intern Med, vol.170, pp.880-887, 2010.

Y. Nussbaumer-ochsner and K. F. Rabe, Systemic manifestations of COPD, Chest, vol.139, pp.165-173, 2011.

M. A. Spruit, S. J. Singh, C. Garvey, R. Zuwallack, L. Nici et al., statement: key concepts and advances in pulmonary rehabilitation, ATS/ERS Task Force on Pulmonary Rehabilitation. An official, vol.188, pp.13-64, 2013.

D. S. Vieira, F. Maltais, and J. Bourbeau, Home-based pulmonary rehabilitation in chronic obstructive pulmonary disease patients, Curr Opin Pulm Med, vol.16, pp.134-143, 2010.

F. Maltais, J. Bourbeau, S. Shapiro, Y. Lacasse, H. Perrault et al., Chronic Obstructive Pulmonary Disease Axis of Respiratory Health Network, Fonds de recherche en santé du Québec. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial, Ann Intern Med, vol.149, pp.869-878, 2008.

C. R. Van-wetering, M. Hoogendoorn, S. J. Mol, M. P. Rutten-van-mölken, and A. M. Schols, Short-and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial, Thorax, vol.65, pp.7-13, 2010.

C. R. Van-wetering, M. Hoogendoorn, R. Broekhuizen, G. J. Geraerts-keeris, D. Munck et al., Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial, J Am Med Dir Assoc, vol.11, pp.179-187, 2010.

M. A. Puhan, E. Gimeno-santos, M. Scharplatz, T. Troosters, E. H. Walters et al., Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease, Cochrane Database Syst Rev, vol.10, p.5305, 2011.

R. Casaburi, D. Kukafka, C. B. Cooper, T. J. Witek, and S. Kesten, Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD, Chest, vol.127, pp.809-817, 2005.

, Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema, Lancet, vol.1, pp.681-686, 1981.

, Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial, Ann Intern Med, vol.93, pp.391-398, 1980.

D. Górecka, K. Gorzelak, P. Sliwi?ski, M. Tobiasz, and J. Zieli?ski, Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia, Thorax, vol.52, pp.674-679, 1997.

A. Chaouat, E. Weitzenblum, R. Kessler, C. Charpentier, M. Enrhart et al., A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients, Eur Respir J, vol.14, pp.1002-1008, 1999.

T. L. Petty, R. E. Stanford, and T. A. Neff, Continuous oxygen therapy in chronic airway obstruction. Observations on possible oxygen toxicity and survival, Ann Intern Med, vol.75, pp.361-367, 1971.

G. A. West and P. Primeau, Nonmedical hazards of long-term oxygen therapy, Respir Care, vol.28, pp.906-912, 1983.

A. Murabit and E. E. Tredget, Review of burn injuries secondary to home oxygen, J Burn Care Res, vol.33, pp.212-217, 2012.

L. Brochard, J. Mancebo, M. Wysocki, F. Lofaso, G. Conti et al., Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease, N Engl J Med, vol.333, pp.817-822, 1995.

J. Bott, M. P. Carroll, J. H. Conway, S. E. Keilty, E. M. Ward et al., Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease, Lancet, vol.341, pp.1555-1557, 1993.

N. Kramer, T. J. Meyer, J. Meharg, R. D. Cece, and N. S. Hill, Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure, Am J Respir Crit Care Med, vol.151, pp.1799-1806, 1995.

P. K. Plant, J. L. Owen, and M. W. Elliott, Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial, Lancet, vol.355, pp.1931-1935, 2000.

S. Nava and N. Hill, Non-invasive ventilation in acute respiratory failure, Lancet, vol.374, pp.250-259, 2009.

S. P. Bhatt, M. W. Peterson, J. S. Wilson, and L. Durairaj, Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial, Int J Chron Obstruct Pulmon Dis, vol.8, pp.581-589, 2013.

B. Lamia, A. Cuvelier, J. Benichou, and J. F. Muir, A multi-centre randomized controlled trial of domiciliary non-invasive ventilation vs long-term oxygen therapy in survivors of acute hypercapnic respiratory failure due to COPD. Non-invasive ventilation in obstructive lung disease (NIVOLD) study

, Rev Mal Respir, vol.29, pp.1141-1148, 2012.

E. Clini, C. Sturani, A. Rossi, S. Viaggi, A. Corrado et al., Ambrosino N; Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO). The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients, Eur Respir J, vol.20, pp.529-538, 2002.

F. M. Struik, R. T. Sprooten, H. A. Kerstjen, G. Bladder, M. Zijnen et al., Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study, Thorax, vol.69, pp.826-834, 2014.

F. M. Struik, Y. Lacasse, R. S. Goldstein, H. A. Kerstjens, and P. J. Wijkstra, Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis, Respir Med, vol.108, pp.329-337, 2014.

T. Kohnlein, W. Windisch, D. Kohler, A. Drabik, J. Geiseler et al., Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial, Lancet Respir Med, vol.2, pp.698-705, 2014.

B. F. Meyers and G. A. Patterson, Chronic obstructive pulmonary disease. 10: Bullectomy, lung volume reduction surgery, and transplantation for patients with chronic obstructive pulmonary disease, Thorax, vol.58, pp.634-638, 2003.

A. Fishman, F. Martinez, K. Naunheim, S. Piantadosi, R. Wise et al., A randomized trial comparing lung-volumereduction surgery with medical therapy for severe emphysema, N Engl J Med, vol.348, pp.2059-2073, 2003.

S. D. Ramsey, K. Berry, R. Etzioni, R. M. Kaplan, S. D. Sullivan et al., Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema, N Engl J Med, vol.348, pp.2092-2102, 2003.

F. C. Sciurba, A. Ernst, F. J. Herth, C. Strange, G. J. Criner et al., A randomized study of endobronchial valves for advanced emphysema, N Engl J Med, vol.363, pp.1233-1244, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00596854

J. D. Christie, L. B. Edwards, A. Y. Kucheryavaya, C. Benden, A. I. Dipchand et al., International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012, J Heart Lung Transplant, vol.31, pp.1073-1086, 2012.

G. Thabut, P. Ravaud, J. D. Christie, Y. Castier, M. Fournier et al., Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.177, pp.1156-1163, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00282520

S. Lahzami, P. O. Bridevaux, P. M. Soccal, J. Wellinger, J. H. Robert et al., Survival impact of lung transplantation for COPD, Eur Respir J, vol.36, pp.74-80, 2010.

A. Eskander, T. K. Waddell, M. E. Faughnan, N. Chowdhury, and L. G. Singer, BODE index and quality of life in advanced chronic obstructive pulmonary disease before and after lung transplantation, J Heart Lung Transplant, vol.30, pp.1334-1341, 2011.

J. B. Orens, M. Estenne, S. Arcasoy, J. V. Conte, P. Corris et al., Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant, vol.25, pp.745-755, 2006.

G. Thabut, J. D. Christie, P. Ravaud, Y. Castier, O. Brugière et al., Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data, Lancet, vol.371, pp.744-751, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00282487

Q. Wang, C. A. Rogers, R. S. Bonser, N. R. Banner, N. Demiris et al.,

, Assessing the benefit of accepting a single lung offer now compared with waiting for a subsequent double lung offer, Transplantation, vol.91, pp.921-926, 2011.

J. C. Munson, J. D. Christie, and S. D. Halpern, The societal impact of single versus bilateral lung transplantation for chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.184, pp.1282-1288, 2011.

A. M. Schols and H. R. Gosker, The pathophysiology of cachexia in chronic obstructive pulmonary disease, Curr Opin Support Palliat Care, vol.3, pp.282-287, 2009.

R. Mostert, A. Goris, C. Weling-scheepers, E. F. Wouters, and A. M. Schols, Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease, Respir Med, vol.94, pp.859-867, 2000.

E. C. Creutzberg, A. Schols, F. Bothmer-quaedvlieg, and E. F. Wouters, Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function, Eur J Clin Nutr, vol.52, pp.396-401, 1998.

R. Hallin, C. Janson, R. H. Arnardottir, R. Olsson, M. Emtner et al., Relation between physical capacity, nutritional status and systemic inflammation in COPD, Clin Respir J, vol.5, pp.136-142, 2011.

P. F. Collins, R. J. Stratton, and M. Elia, Nutritional support in chronic obstructive pulmonary disease: a systematic review and metaanalysis, Am J Clin Nutr, vol.95, pp.1385-1395, 2012.

I. M. Ferreira, D. Brooks, Y. Lacasse, and R. S. Goldstein, Nutritional support for individuals with COPD: a meta-analysis, Chest, vol.117, pp.672-678, 2000.

P. Laveneziana, P. Palange, and . Faculty, Physical activity, nutritional status and systemic inflammation in COPD, Eur Respir J, vol.40, pp.522-529, 2012.

C. Hanson, E. P. Rutten, E. F. Wouters, and S. Rennard, Diet and vitamin D as risk factors for lung impairment and COPD, Transl Res, vol.162, pp.219-236, 2013.

S. M. Bjerk, B. D. Edgington, T. S. Rector, and K. M. Kunisaki, Supplemental vitamin D and physical performance in COPD: a pilot randomized trial, Int J Chron Obstruct Pulmon Dis, vol.8, pp.97-104, 2013.

J. Bourbeau, M. Julien, F. Maltais, M. Rouleau, A. Beaupré et al., Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention, Arch Intern Med, vol.163, pp.585-591, 2003.

C. Hernandez, A. Casas, J. Escarrabill, J. Alonso, J. Puig-junoy et al., Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients, Eur Respir J, vol.21, pp.58-67, 2003.

J. Garcia-aymerich, C. Hernandez, A. Alonso, A. Casas, R. Rodriguez-roisin et al., Effects of an integrated care intervention on risk factors of COPD readmission, Respir Med, vol.101, pp.1462-1469, 2007.

A. Casas, T. Troosters, J. Garcia-aymerich, J. Roca, C. Hernández et al., Integrated care prevents hospitalisations for exacerbations in COPD patients, Eur Respir J, vol.28, pp.123-130, 2006.

K. L. Rice, N. Dewan, H. E. Bloomfield, J. Grill, T. M. Schult et al., Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial, Am J Respir Crit Care Med, vol.182, pp.890-896, 2010.

V. S. Fan, J. M. Gaziano, R. Lew, J. Bourbeau, S. G. Adams et al., A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial, Ann Intern Med, vol.156, pp.673-683, 2012.

F. S. Ram, J. A. Wedzicha, J. Wright, and M. Greenstone, Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence, BMJ, vol.329, p.315, 2004.

T. A. Seemungal and J. A. Wedzicha, Integrated care: a new model for COPD management?, Eur Respir J, vol.28, pp.4-6, 2006.

T. Vontetsianos, P. Giovas, T. Katsaras, A. Rigopoulou, G. Mpirmpa et al., Telemedicine-assisted home support for patients with advanced chronic obstructive pulmonary disease: preliminary results after nine-month follow-up, J Telemed Telecare, vol.11, pp.86-88, 2005.

M. Vitacca, L. Bianchi, A. Guerra, C. Fracchia, A. Spanevello et al., Tele-assistance in chronic respiratory failure patients: a randomised clinical trial, Eur Respir J, vol.33, pp.411-418, 2009.

C. Sicotte, G. Paré, S. Morin, J. Potvin, and M. P. Moreault, Effects of home telemonitoring to support improved care for chronic obstructive pulmonary diseases, Telemed J E Health, vol.17, pp.95-103, 2011.

H. Pinnock, J. Hanley, L. Mccloughan, A. Todd, A. Krishan et al., Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial, BMJ, vol.347, p.6070, 2013.

E. Knauft, E. L. Nielsen, R. A. Engelberg, D. L. Patrick, and J. R. Curtis, Barriers and facilitators to end-of-life care communication for patients with COPD, Chest, vol.127, pp.2188-2196, 2005.

D. H. Au, E. M. Udris, S. D. Fihn, M. B. Mcdonell, and J. R. Curtis, Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer, Arch Intern Med, vol.166, pp.326-331, 2006.

J. R. Curtis, R. A. Engelberg, E. L. Nielsen, D. H. Au, and D. L. Patrick, Patientphysician communication about end-of-life care for patients with severe COPD, Eur Respir J, vol.24, pp.200-205, 2004.

D. H. Au, E. M. Udris, R. A. Engelberg, P. H. Diehr, C. L. Bryson et al., A randomized trial to improve communication about end-of-life care among patients with COPD, Chest, vol.141, pp.726-735, 2012.

M. T. Claessens, J. Lynn, Z. Zhong, N. A. Desbiens, R. S. Phillips et al., Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT, J Am Geriatr Soc, vol.48, pp.146-153, 2000.

P. White, S. White, P. Edmonds, M. Gysels, J. Moxham et al., Palliative care or end-of-life care in advanced chronic obstructive pulmonary disease: a prospective community survey

, Br J Gen Pract, vol.61, pp.362-370, 2011.

D. J. Janssen, M. A. Spruit, N. H. Uszko-lencer, J. M. Schols, and E. F. Wouters, Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure, J Palliat Med, vol.14, pp.735-743, 2011.

M. Gott, C. Gardiner, N. Small, S. Payne, D. Seamark et al., Barriers to advance care planning in chronic obstructive pulmonary disease, Palliat Med, vol.23, pp.642-648, 2009.

D. J. Janssen, J. R. Curtis, D. H. Au, M. A. Spruit, L. Downey et al., Patient-clinician communication about end-of-life care for Dutch and US patients with COPD, Eur Respir J, vol.38, pp.268-276, 2011.

L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. Chaikof et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the, Perioperative Cardiovascular Evaluation for Noncardiac Surgery, 2002.

, American Society of Echocardiography

, Heart Rhythm Society; Society of Cardiovascular Anesthesiologists

, Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery

. Acc/aha, American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery, American College of Cardiology, vol.116, pp.418-499, 2007.

D. Poldermans, J. J. Bax, O. Schouten, A. N. Neskovic, B. Paelinck et al., Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo Study Group. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediaterisk patients receiving beta-blocker therapy with tight heart rate control?, J Am Coll Cardiol, vol.48, pp.964-969, 2006.

D. Poldermans, O. Schouten, R. Vidakovic, J. J. Bax, I. R. Thomson et al., DECREASE Study Group. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study, J Am Coll Cardiol, vol.49, pp.1763-1769, 2007.

E. O. Mcfalls, H. B. Ward, T. E. Moritz, S. Goldman, W. C. Krupski et al., Coronary-artery revascularization before elective major vascular surgery, N Engl J Med, vol.351, pp.2795-2804, 2004.

, British Thoracic Society; Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery, Thorax, vol.56, pp.89-108, 2001.

G. L. Colice, S. Shafazand, J. P. Griffin, R. Keenan, and C. T. Bolliger, Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines, Chest, vol.132, pp.161-177, 2007.

A. Mandra, D. Simi?, V. Stevanovi?, D. Ugrinovi?, V. Skodri? et al., Preoperative considerations for patients with chronic obstructive pulmonary disease, Acta Chir Iugosl, vol.58, pp.71-75, 2011.

A. Brunelli, M. Refai, F. Xiumé, M. Salati, V. Sciarra et al., Performance at symptom-limited stair-climbing test is associated with increased cardiopulmonary complications, mortality, and costs after major lung resection, Ann Thorac Surg, vol.86, pp.247-248, 2008.

T. Win, A. D. Tasker, A. M. Groves, C. White, A. J. Ritchie et al., Ventilation-perfusion scintigraphy to predict postoperative pulmonary function in lung cancer patients undergoing pneumonectomy, AJR Am J Roentgenol, vol.187, pp.1260-1265, 2006.

M. K. Ferguson, L. Little, L. Rizzo, K. J. Popovich, G. F. Glonek et al., Diffusing capacity predicts morbidity and mortality after pulmonary resection, J Thorac Cardiovasc Surg, vol.96, pp.894-900, 1988.

J. S. Wang, Relationship of predicted postoperative product to postpneumonectomy cardiopulmonary complications, J Chin Med Assoc, vol.66, pp.643-654, 2003.

J. S. Wang, Relationship of carbon monoxide pulmonary diffusing capacity to postoperative cardiopulmonary complications in patients undergoing pneumonectomy, Kaohsiung J Med Sci, vol.19, pp.437-446, 2003.

C. T. Bolliger, P. Jordan, M. Solèr, P. Stulz, E. Grädel et al., Exercise capacity as a predictor of postoperative complications in lung resection candidates, Am J Respir Crit Care Med, vol.151, pp.1472-1480, 1995.

D. A. Holden, T. W. Rice, K. Stelmach, and D. P. Meeker, Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection, Chest, vol.102, pp.1774-1779, 1992.

J. Markos, B. P. Mullan, D. R. Hillman, A. W. Musk, V. F. Antico et al., Preoperative assessment as a predictor of mortality and morbidity after lung resection, Am Rev Respir Dis, vol.139, pp.902-910, 1989.

R. J. Pierce, J. M. Copland, K. Sharpe, and C. E. Barter, Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality, Am J Respir Crit Care Med, vol.150, pp.947-955, 1994.

K. Nakahara, Y. Monden, K. Ohno, S. Miyoshi, H. Maeda et al., A method for predicting postoperative lung function and its relation to postoperative complications in patients with lung cancer, Ann Thorac Surg, vol.39, pp.260-265, 1985.

K. Nakahara, K. Ohno, J. Hashimoto, S. Miyoshi, H. Maeda et al., Prediction of postoperative respiratory failure in patients undergoing lung resection for lung cancer, Ann Thorac Surg, vol.46, pp.549-552, 1988.

M. D. Taylor, D. J. Lapar, J. M. Isbell, B. D. Kozower, C. L. Lau et al., Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer, J Thorac Cardiovasc Surg, vol.147, pp.744-746, 2014.

A. Brunelli, A. Refai, M. Monteverde, M. Sabbatini, A. Xiumé et al., Predictors of early morbidity after major lung resection in patients with and without airflow limitation, Ann Thorac Surg, vol.74, pp.999-1003, 2002.

A. Edvardsen, A. Akerø, J. A. Hardie, M. Ryg, T. M. Eagan et al., High prevalence of respiratory symptoms during air travel in patients with COPD, Respir Med, vol.105, pp.50-56, 2011.

S. Ahmedzai, I. M. Balfour-lynn, T. Bewick, R. Buchdahl, R. K. Coker et al., British Thoracic Society Standards of Care Committee. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations, Thorax, vol.66, pp.1-30, 2011.

L. M. Seccombe and M. J. Peters, Oxygen supplementation for chronic obstructive pulmonary disease patients during air travel, Curr Opin Pulm Med, vol.12, pp.140-144, 2006.

A. Akerø, C. C. Christensen, A. Edvardsen, M. Ryg, and O. H. Skjønsberg, Pulse oximetry in the preflight evaluation of patients with chronic obstructive pulmonary disease, Aviat Space Environ Med, vol.79, pp.518-524, 2008.

A. Akerø, A. Edvardsen, C. C. Christensen, J. O. Owe, M. Ryg et al., COPD and air travel: oxygen equipment and preflight titration of supplemental oxygen, Chest, vol.140, pp.84-90, 2011.

M. S. Abdool-gaffar, A. Ambaram, G. M. Ainslie, C. T. Bolliger, C. Feldman et al., Guideline for the management of chronic obstructive pulmonary disease-2011 update, COPD Working Group, vol.101, pp.63-73, 2011.

C. C. Christensen, M. S. Ryg, A. Edvardsen, and O. H. Skjønsberg, Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients, Eur Respir J, vol.24, pp.580-586, 2004.